Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study
Authors:
Open Access
- 24 November 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1716014
Abstract
Background: The relationship between autoantibody profiles and immune checkpoint inhibitor (ICI) therapy in cancer patients remains incompletely characterized. This cross-sectional study investigated serum autoantibody (AAb) prevalence and profiles across multiple tumor types before and after ICI therapy. Methods: This study analyzed serum autoantibodies in 808 participants: 358 treatment-naïve cancer patients (ICI- group), 250 cancer patients following ≥6 months of ICI therapy (ICI+ group), and 200 healthy controls (HC). The cancer cohort comprised 10 solid tumor types. Serum samples were analyzed for antinuclear antibodies (ANA), antiphospholipid antibodies (aPL), anti-neutrophil cytoplasmic antibodies (ANCA), and anti-thyroid antibodies (ATA) using automated quantitative immunoassays. Results: Cancer patients demonstrated significantly elevated AAb prevalence compared to healthy controls. The ICI− group showed positivity rates of 20.1% for ANA, 11.5% for aPL, 1.7% for ANCA, and 17.3% for ATA, compared to 10.5%, 4.5%, 1.5%, and 9.5% in healthy controls, respectively. After ICI therapy, ANA positivity increased to 33.6%. CTLA-4 inhibitor recipients demonstrated higher ANA frequencies than PD-1/PD-L1 monotherapy recipients (57.1% vs 27.1%),. Tumor stage did not significantly influence AAb prevalence. Colorectal, hepatocellular, and renal cancers showed significant ANA increases after ICI treatment. Anti-Scl-70, anti-SSA-60, and anti-RNP were the most frequently elevated ANA subtypes. Anti-thyroglobulin was the most responsive ATA subtype following ICI therapy. Conclusions: ANA profiles vary across tumor types and differ between treatment-naïve and ICI-treated patients. CTLA-4-treated patients exhibit higher ANA frequency. Different tumors exhibit distinct preferences for AAb expression patterns. Serum AAb profiling may serve as a valuable tool for immunotherapy monitoring and risk stratification for immune-related adverse events.Keywords
This publication has 52 references indexed in Scilit:
- Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohortClinical and Experimental Medicine, 2024
- Thyroid disorders induced by immune checkpoint inhibitorsEndocrine, 2024
- Evaluation of autoantibodies as predictors of treatment response and immune‐related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan‐cancer studyCancer Medicine, 2022
- IgA anti-beta-2 glycoprotein I antibodies in chronic hepatitis CArab Journal of Gastroenterology, 2022
- The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysisAutoimmunity Reviews, 2021
- Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studiesAutoimmunity Reviews, 2020
- Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patientsMedical Oncology, 2020
- Antinuclear antibodies in patients with cervical lesions and invasive cervical cancerImmunology Letters, 2019
- The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence testImmunologic Research, 2016
- Prevalence and sociodemographic correlates of antinuclear antibodies in the United StatesArthritis & Rheumatism, 2012